Amprenavir
- Generic Name
- Amprenavir
- Drug Type
- Small Molecule
- Chemical Formula
- C25H35N3O6S
- CAS Number
- 161814-49-9
- Unique Ingredient Identifier
- 5S0W860XNR
- Background
Amprenavir is a protease inhibitor used to treat HIV infection.
- Indication
用于高效抗逆转录病毒疗法（HAART）的组成药物。
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 60
- Registration Number
- NCT00002183
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Study of Amprenavir in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002405
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00002193
- Locations
- 🇺🇸
Children's Diagnostic Treatment Ctr, Fort Lauderdale, Florida, United States
🇺🇸Saint Jude Children's Hosp / Dept of Infect Diseases, Memphis, Tennessee, United States
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 30
- Registration Number
- NCT00002233
- Locations
- 🇺🇸
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States
🇺🇸Miriam Hosp / Family Healthcare Ctr at SSTAR, Providence, Rhode Island, United States
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT00002239
- Locations
- 🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States
A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002216
- Locations
- 🇺🇸
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 94
- Registration Number
- NCT00001095
- Locations
- 🇺🇸
St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States
🇺🇸Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
- Conditions
- HIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00001758
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.